Earlier, drug maker Regeneron Pharmaceuticals was set to buy 23andMe. Then a bankruptcy judge reopened the bidding process to allow for a bid from TTAM, which offered a higher price.

Sale trumps Regeneron bid The sale to TTAM replaces a $256 million bid for 23andMe by drug maker Regeneron made in May. "We are pleased that the competitive bidding process has resulted in ...

Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a $305 million acquisition by her nonprofit TTAM Research Institute, the ...

The "ultimate insiders" is what Regeneron Pharmaceuticals Inc. called Wojcicki and TTAM in late May, after the drugmaker won the initial auction for 23andMe with a $256 million bid.

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge greenlighted the sale of the remnants of the firm, including its wealth ...

And in a memorandum opinion outlining his approval 23andMe's sale to TTAM on Friday, Walsh acknowledged these states' objections to the acquisition — but that noted many had since been resolved.

During the bankruptcy proceedings, New York-based Regeneron Pharmaceuticals won an auction to acquire the company for $256 million. Subsequently, a group of 27 states and the District of Columbia ...

Genetic testing company 23andMe never hit on a sustainable business model and went bankrupt. Now, it's being sold to a non-profit launched by the co-founder, delaying addressing data privacy concerns.

Sale trumps Regeneron bid The sale to TTAM replaces a $256 million bid for 23andMe by drug maker Regeneron made in May. "We are pleased that the competitive bidding process has resulted in ...

A bankruptcy judge approved the sale of genetics company 23andMe to a non-profit led by co-founder and former CEO Anne Wojcicki, according to a June 27 filing in the bankruptcy docket.